A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils

  • Dabscheck, Eli (Primary Chief Investigator (PCI))
  • Hazard, Anita (Project Manager)

Project: Research

Project Details

Effective start/end date30/06/2031/12/24


  • Respiratory medicine
  • chronic obstructive pulmonary disease (COPD)
  • Clinical trial